Volume 118, Issue 6 pp. 1453-1459
Early Detection and Diagnosis

Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue

Menelaos Zafrakas

Menelaos Zafrakas

Institute of Pathology, University Hospital of the RWTH, Aachen, Germany

Department of Gynecology, Breast Surgery and Mastology, University Hospital Aachen, Germany

Search for more papers by this author
Marina Chorovicer

Marina Chorovicer

Institute of Pathology, University Hospital of the RWTH, Aachen, Germany

Search for more papers by this author
Irima Klaman

Irima Klaman

Institute of Pathology, Emil-von-Behring Hospital, Berlin, Germany

Search for more papers by this author
Glen Kristiansen

Glen Kristiansen

Institute of Pathology, Charité University Hospital, Berlin, Germany

Search for more papers by this author
Peter-Johannes Wild

Peter-Johannes Wild

Institute of Pathology, University of Regensburg, Regensburg, Germany

Search for more papers by this author
Uwe Heindrichs

Uwe Heindrichs

Department of Gynecology, Breast Surgery and Mastology, University Hospital Aachen, Germany

Search for more papers by this author
Ruth Knüchel

Ruth Knüchel

Institute of Pathology, University Hospital of the RWTH, Aachen, Germany

Search for more papers by this author
Edgar Dahl

Corresponding Author

Edgar Dahl

Institute of Pathology, University Hospital of the RWTH, Aachen, Germany

Fax: +49-241-8082439.

Institut für Pathologie, Universitätsklinikum Aachen, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, GermanySearch for more papers by this author
First published: 18 January 2006
Citations: 33

Abstract

The GABRP gene has been previously identified by in silico analysis of four million ESTs as a candidate gene differentially expressed in breast cancer. GABRP is located on chromosome 5q34 and it encodes the π-subunit of the γ-aminobutyric acid (GABA) receptor, a transmembrane protein expressed in the brain and several nonneuronal tissues. Using cDNA dot blot hybridisation (cancer profiling array), quantitative RT-PCR and non-radioisotopic in situ hybridisation (ISH), we have analysed GABRP expression in breast cancer and normal breast tissues as well as in nontumorigenic and tumorigenic breast cell lines. Analysis of the cancer profiling array revealed a more than 2-fold downregulation of GABRP (p < 0.001) in 76% of primary breast carcinomas (n = 50) compared to corresponding normal tissues. Quantitative RT-PCR in a panel of 23 normal human tissues showed that the GABRP expression level was most abundant in the normal breast tissues compared to other human tissues. GABRP downregulation in breast cancer was confirmed by quantitative RT-PCR in cryopreserved breast tumour and normal breast tissue specimens (n = 22), in archival formalin-fixed, paraffin-embedded tissue specimens (n = 32), as well as in breast cancer cell lines (n = 8). Furthermore, a significant downregulation of GABRP was noted in large (pT3-pT4) (p = 0.044) primary breast tumours. Non-radioisotopic ISH showed strong GABRP expression in normal epithelial and benign papilloma breast cells, but no signal could be detected in invasive ductal carcinoma. Altogether, these data suggest that GABRP is progressively down-regulated with tumour-progression, and that it may be useful as a prognostic marker in breast cancer. © 2005 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.